Polynovo Ltd
Company Profile
Business description
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
Contact
320 Lorimer Street
Unit 2
Port MelbourneVIC3207
AUST: +61 386814050
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2025
Employees
8
Stocks News & Analysis
stocks
What we think of the 3 biggest losers of the ASX 100
stocks
Wrapped: Spotify's hard earned moat
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,689.30 | 55.20 | -0.63% |
| CAC 40 | 7,426.88 | 96.34 | 1.31% |
| DAX 40 | 20,384.61 | 25.81 | 0.13% |
| Dow JONES (US) | 44,676.66 | 89.05 | -0.20% |
| FTSE 100 | 8,308.61 | 40.77 | -0.49% |
| HKSE | 19,865.85 | 305.41 | 1.56% |
| NASDAQ | 19,825.73 | 125.01 | 0.63% |
| Nikkei 225 | 39,091.17 | 304.43 | -0.77% |
| NZX 50 Index | 12,809.59 | 87.36 | -0.68% |
| S&P 500 | 6,086.33 | 11.22 | 0.18% |
| S&P/ASX 200 | 8,420.90 | 54.00 | -0.64% |
| SSE Composite Index | 3,404.08 | 35.22 | 1.05% |